Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paclitaxel
Drug ID BADD_D01653
Description Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Indications and Usage Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Marketing Status approved; vet_approved
ATC Code L01CD01
DrugBank ID DB01229
KEGG ID D00491
MeSH ID D017239
PubChem ID 36314
TTD Drug ID D0C4RB
NDC Product Code 0703-3213; 52222-0001; 65129-1308; 68083-179; 69539-159; 62422-0004; 68001-516; 68083-178; 0703-4768; 68554-0061; 46708-622; 47781-595; 62332-621; 62332-622; 63323-763; 72205-063; 60505-6230; 62332-620; 72205-062; 0517-4300; 0703-3216; 0703-3218; 17359-3055; 63126-902; 69539-158; 72205-061; 17359-4056; 49452-4961; 51446-0110; 59651-605; 0703-4764; 51446-0120; 46708-620; 61703-342; 68083-180; 0703-3217; 17359-4040; 62422-0002; 69539-157; 70860-215; 42533-111; 54893-0007; 65129-2039; 69443-022; 16714-137; 68817-134; 70860-200; 17359-4055; 65892-002; 24979-710; 46708-621
UNII P88XT4IS4D
Synonyms Paclitaxel | Anzatax | NSC-125973 | NSC 125973 | NSC125973 | Taxol | Taxol A | Bris Taxol | Taxol, Bris | Paclitaxel, (4 alpha)-Isomer | Paxene | Praxel | 7-epi-Taxol | 7 epi Taxol | Onxol
Chemical Information
Molecular Formula C47H51NO14
CAS Registry Number 33069-62-4
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6) O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Non-small cell lung cancer metastatic22.08.01.021; 16.19.01.0090.001254%Not Available
Communication disorder19.19.01.0080.000112%Not Available
Foot deformity15.10.03.0050.000168%Not Available
Retinoschisis06.09.03.0250.000112%Not Available
Foaming at mouth17.02.05.056; 08.01.03.070; 07.05.05.0190.000168%Not Available
Acute left ventricular failure02.05.02.0050.000112%Not Available
Renal embolism24.01.11.003; 20.01.07.0140.000112%Not Available
Metastatic gastric cancer16.13.03.004; 07.21.02.0040.000168%Not Available
Onychalgia23.02.05.0260.000280%Not Available
Fistula of small intestine12.02.03.026; 07.11.05.0100.000112%
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000392%Not Available
Oral mucosal erythema07.05.05.0230.000224%Not Available
Neurosensory hypoacusis04.02.01.015; 17.04.07.0070.000112%Not Available
Skin plaque23.03.03.0440.000112%Not Available
Butterfly rash23.03.13.019; 15.06.02.010; 10.04.03.0100.000112%Not Available
Decreased eye contact19.01.02.012; 17.02.05.0550.000224%Not Available
Band sensation17.16.01.0040.000280%Not Available
Exposed bone in jaw15.02.04.0340.000280%Not Available
Seizure like phenomena17.12.03.0300.000112%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.000895%Not Available
Pseudocirrhosis16.32.03.027; 09.01.04.0090.000280%Not Available
Pharyngeal paraesthesia22.04.05.018; 17.02.06.0350.000414%Not Available
Administration site extravasation12.07.04.019; 08.02.04.0190.000168%Not Available
Angiosarcoma recurrent24.03.06.011; 16.16.03.0030.000112%Not Available
Ankyloglossia acquired07.14.01.0170.000168%Not Available
Biliary obstruction09.02.02.0050.000168%Not Available
Cancer fatigue08.01.01.015; 16.32.03.0350.000112%Not Available
Cardiac perfusion defect02.02.02.023; 24.04.04.0270.000112%Not Available
Catheter site swelling08.02.02.005; 12.07.02.0050.000112%Not Available
Catheter site warmth12.07.02.031; 08.02.02.0310.000112%Not Available
The 26th Page    First    Pre   26 27    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene